Acronym:
14D-MC-JTJN
ACTRN/NCT /ethics:
Scientific title:
Summary of trial and patient characteristics
| Cancer Type | Gynaecological | ||
|---|---|---|---|
| Trial Type | Treatment | ||
| Phase | Phase II | Tumour Stream | Ovarian |
| Age Range | 18 years and older | Cancer Stage | Locally Recurrent or Locally Advanced |
| Sex | Female | Anticipated Start Date | |
| Molecular Target | Anticipated End Date | ||
| Cancer Type | Gynaecological |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | Female |
| Molecular Target | |
| Tumour Stream | Ovarian |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | |
| Anticipated End Date |
Trial Summary
A phase II study of rexasertib in platinum-resistant or refractory recurrent ovarian cancer.
Lay Summary
Sponsor / Cooperative group
Participating Hospitals
| Hospital | Clinical Trial Coordinator | Phone | Principal Investigator | Recruitment Status | |
|---|---|---|---|---|---|
| Flinders Medical Centre | Alex Scott-Hoy | alex.scott-hoy@sa.gov.au | 08 8204 4830 | Ganessan Kichenadasse | Recruiting |